钆塞酸二钠增强MRI与扩散加权成像在检出药物洗脱微球经动脉化疗栓塞术后残余肝细胞癌中的价值
回顾性分析62例患者74个肝细胞癌病灶,在药物洗脱微球经动脉化疗栓塞术后1–2个月行钆塞酸二钠增强MRI与DWI,以病理和/或血管造影为参考标准。残余灶33个、坏死灶41个;钆塞酸二钠增强MRI诊断残余灶的敏感度和特异度均高于DWI(96.97% vs 78.79%,100% vs 78.05%)。
要点
- 术后1–2个月评估时,动脉期富血供与DWI高信号是鉴别残余灶与坏死灶的重要征象。
- 钆塞酸二钠增强MRI诊断残余灶的敏感度96.97%、特异度100%,均高于DWI。
- DWI联合ADC阈值1.25×10-3 mm2/s诊断残余灶的敏感度84.85%、特异度87.80%。
核心结论
- 钆塞酸二钠增强MRI诊断药物洗脱微球经动脉化疗栓塞术后残余肝细胞癌优于DWI,动脉期富血供和DWI高信号是鉴别残余灶与坏死灶的重要影像特征。
研究设计与样本
- 回顾性研究,纳入62例患者(男50例、女12例,平均年龄56.8±1.4岁)共74个肝细胞癌病灶,在药物洗脱微球经动脉化疗栓塞术后1–2个月行钆塞酸二钠增强MRI和DWI,以病理和/或血管造影为参考标准。
关键影像表现/征象
- 残余肝细胞癌表现为动脉期富血供(90.91%)和DWI高信号(78.78%),这两项特征在鉴别坏死灶方面有重要意义(p<0.05)。
诊断标准与关键数值
- 残余灶平均ADC值1.30±0.32×10-3 mm2/s vs 坏死灶1.55±0.50×10-3 mm2/s,p<0.001;原文表述为残余灶平均ADC值显著高于坏死灶,但所给数值中残余灶低于坏死灶,原文此处数值与文字方向矛盾。
临床应用与阅片要点
- 术后1–2个月阅片时,应结合动脉期富血供与DWI高信号判断有无残余灶,增强MRI对残余灶的检出敏感度和特异度均高于DWI。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: To investigate the value of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) and diffusion-weighted imaging (DWI) in diagnosing residual hepatocellular carcinoma (HCC) after drug-eluting bead transarterial chemoembolization (DEB-TACE).
MATERIALS AND METHODS: Sixty-two patients (50 men, 12 women; mean age, 56.8 ± 1.4 years) with 74 HCCs who underwent Gd-EOB-DTPA-enhanced MRI and DWI in 1-2-month intervals after DEB-TACE were retrospectively studied. Imaging features derived from Gd-EOB-DTPA-enhanced MRI and DWI were analyzed and compared between residual HCCs and necrotic tumors. The sensitivity and specificity of Gd-EOB-DTPA-enhanced MRI and DWI with quantitative apparent diffusion coefficient (ADC) values in diagnosing residual HCCs were calculated and compared, based on the reference standard of pathology and/or angiography.
RESULTS: Thirty-three residual HCCs and 41 necrotic tumors were diagnosed. Residual HCCs presented characteristics of arterial hypervascularity (90.91%) and DWI hyperintensity (78.78%), which were of importance in differentiating necrotic tumors (p< 0.05). DWI showed lower sensitivity (78.79% vs. 96.97%, p< 0.001) and specificity (78.05% vs. 100%, p< 0.001) than Gd-EOB-DTPA-enhanced MRI in diagnosing residual HCCs after DEB-TACE. Residual HCCs had a significantly higher mean ADC value than necrotic tumors (1.30 ± 0.32 × 10-3 mm2/s vs. 1.55 ± 0.50 × 10-3 mm2/s, p< 0.001). Receiver operating characteristic curve analysis for identifying residual HCCs demonstrated that the threshold ADC value of 1.25 × 10-3 mm2/s had 84.85% sensitivity and 87.80% specificity.
CONCLUSION: Gd-EOB-DTPA-enhanced MRI is superior to DWI in diagnosing residual HCCs after DEB-TACE, and arterial hypervascularity and DWI hyperintensity are important imaging features in distinguishing residual HCCs from necrotic tumors.
引用
- Liu HF, Xu YS, Liu Z, et al. Value of Gd-EOB-DTPA-Enhanced MRI and Diffusion-Weighted Imaging in Detecting Residual Hepatocellular Carcinoma After Drug-Eluting Bead Transarterial Chemoembolization. Acad Radiol. 2020. PMID: 32414638. doi:10.1016/j.acra.2020.04.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。